Skip to main content
  • FOR CONSUMERS
  • CONTACT US

combined bayer and aspirin logo

ATTENTION

The information on this page is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL

aleve log
  • PRODUCTS
    • Products
      • Aleve® Caplets & Tablets
      • Aleve® Liquid Gels
      • Aleve® Gelcaps
      • Aleve® PM
      • Aleve-D®
  • EFFICACY AND PAIN GUIDELINES
    Aleve product bottle
    • Efficacy and Pain Guidelines
      • Dental Pain Studies and Guidelines
      • Primary Dysmenorrhea Study and Guidelines
      • Osteoarthritis Pain Studies and Guidelines
      • Musculoskeletal Pain Studies and Guidelines
      • Additional Clinical Materials
  • Safety
  • FAQ
  • SAMPLES
  • Resources
Bayer Cross Logo
  1. Home
  2. Efficacy and Pain Guidelines
  3. Dental Pain Studies and Guidelines
  4. Non-Opioid Dental Pain Relief
  5. Aleve® vs HYD + APAP

Aleve® as strong* on pain as HYD+APAP and longer lasting.1

*Based on a clinical study vs hydrocodone plus acetaminophen (HYD+APAP) during the first  4 hours after initial dosing.
Use as directed for minor aches and pains.

AS STRONG AS

LONGER LASTING

BETTER TOLERATED

Aleve®, a non-opioid OTC NSAID, was compared with HYD+APAP for dental pain relief1 in a recent, single-center, randomized, double-blind, parallel, placebo-controlled single-dose study.1

  • Patients experiencing moderate or severe pain (N=221) after surgical removal of impacted third molars were randomized to receive either a single dose of Aleve® (440 mg [n=90]), HYD+APAP (10 mg + 650 mg [n=87]), or placebo (n=44)
  • The primary objective was to compare Sum of Pain Intensity Difference from 0 to 12 hours (SPID0-12) after a single oral dose
    • Secondary objectives were to compare the total pain relief (TOTPAR) over 6 and 12 hours, SPID0-6, time to onset of pain relief, time to first use of rescue medication, and duration of pain intensity at least half gone over 6 and 12 hours
    • SPID0-4 was also assessed

In the study, Aleve® was as effective† as HYD+APAP at hours 0 to 4 at reducing pain intensity1,‡

STUDY RESULTS
The primary endpoint was met

SPID0-12 was statistically significant for Aleve® vs HYD+APAP.

 

Key secondary endpoints also showed statistical significance compared with HYD+APAP:

  • TOTPAR (0 to 6 and 0 to 12 hours; P<0.05)
  • Median time to rescue medication (P<0.001)
  • Duration of pain at least half gone over 12 hours (P<0.001)
 

Both active treatments were significantly more effective than placebo

HYD+APAP was not statistically superior to Aleve® for any endpoint.

 

†In hours 0 to 4 of a single-dose dental study of Aleve® (440 mg), hydrocodone plus acetaminophen, HYD+APAP (10 mg + 650 mg), or placebo.1

‡Based on SPID0-4.

 

mean_pain_intensity_difference_chart.

 

rescue_medication_chart

 

better_tolerated_chart.

More treatment-related adverse events were reported with HYD+APAP (n=18) than Aleve® (n=1), including nausea, vomiting, and dizziness.1

The growing body of evidence offers a compelling argument for first-line use of an NSAID like Aleve®, and professional organization guidelines suggest ways of putting NSAIDs into practice.1-8

When prescribing any product, HCPs should always consider its efficacy and safety. Before any procedure requiring pain management, HCPs should talk with patients about the benefits and risks.

Image

References: 1. Cooper SA, Desjardins PJ, Bertoch T, et al. Analgesic efficacy of naproxen sodium versus hydrocodone/acetaminophen in acute postsurgical dental pain: a randomized, double-blind, placebo-controlled trial. Postgrad Med. 2021. doi:10.1080/00325481.2021.2008180 2. Data on file. Bayer Consumer Health. 3. Kiersch TA, Halladay SC, Hormel PC. A single-dose, double-blind comparison of naproxen sodium, acetaminophen, and placebo in postoperative dental pain. Clin Ther. 1994;16(3):394-404. 4. American Dental Association announces new policy to combat opioid epidemic. News release. American Dental Association. March 26, 2018. Accessed May 25, 2023. https://www.prnewswire.com/news-releases/american-dental-association-announces-new-policy-to-combat-opioid-epidemic-300618928.html 5. American Dental Association. Statement on the use of opioids in the treatment of dental pain. October 2016. Accessed May 25, 2023. https://www.ada.org/about/governance/current-policies#substanceusedisorders 6. American Association of Oral and Maxillofacial Surgeons. Opioid prescribing: acute and postoperative pain management; 2020. White Paper. Accessed May 25, 2023. https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/opioid_prescribing.pdf 7. American Academy of Orthopaedic Surgeons. Management of osteoarthritis of the knee (non-arthroplasty). Evidence-based clinical practice guideline. May 1, 2022. Accessed June 15, 2023. https://journals.lww.com/jaaos/Fulltext/2022/05010/AAOS_Clinical_Practice_Guideline_Summary_.10.aspx 8. Kolasinksi SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 202;72(2): 220-233. doi:10.1002/art.41142

  • Efficacy and Pain Guidelines
  • Understanding Pain
  • Safety
  • FAQ
  • Samples
  • Resources
  • For Patients
  • Contact Us
  • Aleve® Products
    • Aleve® Caplets
    • Aleve® Tablets
    • Aleve® Liquid Gels
    • Aleve® Gelcaps
    • Aleve® PM
    • Aleve-D®
  • Site Map

©2023. All rights reserved. Unless otherwise indicated, all trademarks are owned by Bayer and its affiliates, or licensed for its use.

USE AS DIRECTED

  • Bayer Global
  • Bayer US
  • Bayer Consumer Health
  • Conditions of Use
  • Privacy Statement
  • Imprint
  • California Transparency in Supply Chains
  • Satisfaction Guarantee
  • AdChoices
  • Do not sell or share my Personal Data
  • Accessibility

Level Access website accessibility icon